55 related articles for article (PubMed ID: 15046039)
1. Lack of descriptive support results in no interference-in-fact.
Nat Rev Drug Discov; 2004 Mar; 3(3):196. PubMed ID: 15046039
[No Abstract] [Full Text] [Related]
2. Drug discovery. Magnificent obsession.
Couzin J
Science; 2005 Mar; 307(5716):1712-5. PubMed ID: 15774740
[No Abstract] [Full Text] [Related]
3. CD40-expressing carcinoma cells induce down-regulation of CD40 ligand (CD154) and impair T-cell functions.
Batrla R; Linnebacher M; Rudy W; Stumm S; Wallwiener D; Gückel B
Cancer Res; 2002 Apr; 62(7):2052-7. PubMed ID: 11929824
[TBL] [Abstract][Full Text] [Related]
4. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
5. Use of anti-CD40 ligand monoclonal antibody as antirejection therapy in a murine peripheral nerve allograft model.
Jensen JN; Tung TH; Mackinnon SE; Brenner MJ; Hunter DA
Microsurgery; 2004; 24(4):309-15. PubMed ID: 15274190
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic CD154 antibody for lupus: promise for the future?
Kelsoe G
J Clin Invest; 2003 Nov; 112(10):1480-2. PubMed ID: 14617748
[TBL] [Abstract][Full Text] [Related]
7. [CD 40 L blockade as a novel treatment for chronic ITP refractory to corticosteroids and splenectomy].
Kuwana M
Rinsho Ketsueki; 2003 Feb; 44(2):82-9. PubMed ID: 12692980
[No Abstract] [Full Text] [Related]
8. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse.
Komura K; Fujimoto M; Yanaba K; Matsushita T; Matsushita Y; Horikawa M; Ogawa F; Shimizu K; Hasegawa M; Takehara K; Sato S
Ann Rheum Dis; 2008 Jun; 67(6):867-72. PubMed ID: 17823201
[TBL] [Abstract][Full Text] [Related]
9. Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse.
Nanji SA; Hancock WW; Luo B; Schur CD; Pawlick RL; Zhu LF; Anderson CC; Shapiro AM
Diabetes; 2006 Jan; 55(1):27-33. PubMed ID: 16380473
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD40 ligand monoclonal antibody induces a permissive state, but not tolerance, for murine peripheral nerve allografts.
Brenner MJ; Tung TH; Mackinnon SE; Myckatyn TM; Hunter DA; Mohanakumar T
Exp Neurol; 2004 Mar; 186(1):59-69. PubMed ID: 14980810
[TBL] [Abstract][Full Text] [Related]
11. Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation.
Li XL; Ménoret S; Le Mauff B; Angin M; Anegon I
Transplantation; 2008 Jul; 86(1):10-5. PubMed ID: 18622269
[TBL] [Abstract][Full Text] [Related]
12. Characterization and application of two novel monoclonal antibodies against CD40L: epitope and functional studies on cell membrane CD40L and studies on the origin of soluble serum CD40L.
Fan Y; Ge Y; Zhu H; Wang Y; Yang B; Zhuang Y; Ma H; Zhang X
Tissue Antigens; 2004 Sep; 64(3):257-63. PubMed ID: 15304006
[TBL] [Abstract][Full Text] [Related]
13. The effect of anti-CD40 ligand in immune thrombocytopenic purpura.
Patel VL; Schwartz J; Bussel JB
Br J Haematol; 2008 May; 141(4):545-8. PubMed ID: 18341638
[TBL] [Abstract][Full Text] [Related]
14. Production and characterization of agonistic monoclonal antibodies against chicken CD40.
Chen CH; Abi-Ghanem D; Njongmeta L; Bray J; Mwangi W; Waghela SD; McReynolds JL; Ing NH; Berghman LR
Dev Comp Immunol; 2010 Nov; 34(11):1139-43. PubMed ID: 20599554
[TBL] [Abstract][Full Text] [Related]
15. CD40 ligand expression on stimulated T-helper lymphocytes in patients with common variable immunodeficiency.
Ravanbakhsh M; Sarafnejad A; Aghamohammadi A; Kardar GA; Asgarian Omran H; Atarod L; Rezaei N; Shahrestani T; Hosseini M; Moin M
Iran J Allergy Asthma Immunol; 2007 Sep; 6(3):129-35. PubMed ID: 17893433
[TBL] [Abstract][Full Text] [Related]
16. CD154 and its receptors in inflammatory vascular pathologies.
Hassan GS; Merhi Y; Mourad WM
Trends Immunol; 2009 Apr; 30(4):165-72. PubMed ID: 19282242
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors.
Ewenstein BM; Hoots WK; Lusher JM; DiMichele D; White GC; Adelman B; Nadeau K
Haematologica; 2000 Oct; 85(10 Suppl):35-9. PubMed ID: 11187868
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key.
Bachmann MF; Hunziker L; Zinkernagel RM; Storni T; Kopf M
Eur J Immunol; 2004 Feb; 34(2):317-26. PubMed ID: 14768036
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of T cell activation by immobilized hu5C8 (anti-CD40L) monoclonal antibody.
Arpinati M; Chirumbolo G; Rondelli D
Eur J Haematol; 2008 Apr; 80(4):322-30. PubMed ID: 18081708
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.
Davis JC; Totoritis MC; Rosenberg J; Sklenar TA; Wofsy D
J Rheumatol; 2001 Jan; 28(1):95-101. PubMed ID: 11196549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
